Arcus Biosciences, Inc. (RCUS) Profit Margins
Over the twelve months to 2026-06-30, Arcus Biosciences, Inc. (RCUS) had operating margin -415.4%, net margin -393.2%, free cash flow margin -406.0%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCUSArcus Biosciences, Inc.Follow RCUS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 92.2% | — | — | |
| Operating margin | -591.4% | -159.0% | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% | -415.4% | |
| Net margin | -564.7% | -157.7% | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% | -393.2% | |
| FCF margin | -502.6% | 138.5% | -73.6% | 385.7% | -282.1% | -68.2% | -196.0% | -406.0% |
USD billions · SEC XBRL
Arcus Biosciences, Inc. — questions
- What is Arcus Biosciences, Inc.'s operating margin?
- -415.4% over the twelve months to 2026-06-30.
- What is Arcus Biosciences, Inc.'s net profit margin?
- -393.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Arcus Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.